402 related articles for article (PubMed ID: 22993103)
1. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
2. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
6. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
9. Role of tumour angiogenesis in haematological malignancies.
Medinger M; Passweg J
Swiss Med Wkly; 2014; 144():w14050. PubMed ID: 25375891
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
11. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis: a new therapeutic target of thoracic and laryngopharyngeal carcinoma].
Taillade L; Alexandre I; Billemont B; Meric JB; Sultan-Amar V; Rixe O
Bull Cancer; 2009; 96 Suppl 1():S45-55. PubMed ID: 19433373
[TBL] [Abstract][Full Text] [Related]
13. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
15. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
16. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
19. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]